Eagle Therapeutics

Eagle Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing innovative medicines in oncology, critical care, and orphan diseases. The company primarily utilizes the 505(b)(2) regulatory pathway to improve upon existing drug formulations, aiming to provide meaningful benefits such as enhanced efficacy, safety, or ease of administration. Its commercial portfolio includes key products like Bendeka for leukemia, Ryanodex for malignant hyperthermia, and Pemfexy for lung cancer. Eagle's late-stage pipeline features EA-114, a proprietary formulation of fulvestrant for breast cancer, and CAL02, a novel anti-toxin agent for severe pneumonia. The company is headquartered in New Jersey and maintains a research and development facility in Cambridge, Massachusetts.